Serum Annexin A2 Level Is Associated With Diagnosis and Prognosis in Patients With Oral Squamous Cell Carcinoma

Zhang, Wei; Gao, Chunhai; Zhang, Shaohua; Fang, Guiqing

doi:10.1016/j.joms.2016.10.032

Cited by 13 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Kaplan-Meier survival analysis found that patients with ANXA2 negative expression had a significantly longer overall survival than those with www.nature.com/scientificreports/ ANXA2 positive expression. And Cox multivariate analysis showed that ANXA2 positive expression was an independent risk factors for the survival of OSCC patients, which was in accordance with the results of Zhang et al 17 . However, it still need to do more in-depth statistical analysis with large samples to verify the relationship of ANXA2 and prognosis and survival of OSCC patients.…”

Section: Discussionsupporting

confidence: 90%

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Wang

2021

Sci Rep

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is the most common malignant epithelial neoplasm of the head and neck, with poorer prognosis. There is lack of specific targets for diagnosis and treatment of OSCC at present. Annexin A2 (ANXA2) is involved in cell angiogenesis, invasion, proliferation and metastasis. In this study, the significance and effect of ANXA2 on OSCC and OSCC cells were explored from the clinical and basic study. First, ANXA2 expression in OSCC tissues and adjacent non-cancer tissues of 124 patients were detected, and the correlation between ANXA2 expression and clinical parameters were analyzed. The results found that ANXA2 was highly expressed in OSCC tissues, and was associated with the TNM stage, tumor differentiation, lymph node metastasis and poor survival of OSCC patients. The expression of ANXA2 in OSCC cells were higher than the normal oral cells. And knockdown of ANXA2 by transfecting ANXA2-siRNA could suppress the proliferation, migration, and invasion abilities of OSCC cells. Overall, ANXA2 expression is correlated with poor survival of OSCC patients, and silencing of ANXA2 suppress the proliferation, migration and invasion of OSCC cells.

show abstract

Section: Discussionsupporting

confidence: 90%

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Wang

2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Structurally, annexin A2 is a 36 kDa peripheral membrane protein that belongs to the annexin family of calcium- and phospholipid-binding proteins composed of 12 paralogs in humans and is originally characterized by the ability to bind and aggregate anionic phospholipid membranes in a calcium-dependent manner [5]. Abnormal expression of annexin A2 was found in hepatocellular carcinoma and other types of tumors, such as pancreatic cancer [6, 7], gastric adenocarcinoma [8], prostate carcinoma [9], high-grade glioma [10], oral squamous cell carcinoma [11], and breast cancer [12]. Overexpression of annexin 2 is involved in several pathological processes, such as tumor cell adhesion, proliferation, apoptosis, tumor neoangiogenesis, invasion, and metastasis [13].…”

Section: Introductionmentioning

confidence: 99%

High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma

et al. 2019

View full text Add to dashboard Cite

Objective. Accumulating evidence suggests that pseudogenes play potential roles in the regulation of their cognate wild-type genes, oncogenes, and tumor suppressor genes. ANXA2P2 (annexin A2 pseudogene 2) is one of three pseudogenes of annexin A2 that have recently been shown to be aberrantly transcribed in hepatocellular carcinoma (HCC) cells. However, its clinical meaning and biological function in HCC have remained unclear. Therefore, the present study was aimed at exploring the prognostic value of a high expression of ANXA2P2 in HCC tissue and at identifying whether it can affect the efficacy of targeted drugs (sorafenib, regorafenib, and lenvatinib). Methods. We obtained ANXA2P2 mRNA expression levels from The Cancer Genome Atlas (TCGA) RNA sequence database. The expression levels of ANXA2P2 in 49 pairs of intratumoral and peritumoral liver tissues were examined by RT-PCR. Wound healing and transwell assays were performed to confirm the tumor-promoting properties of ANXA2P2 in HCC cells. CCK8 assay was conducted to identify whether ANXA2P2 can affect the growth of HCC cells when administered with targeted drugs (sorafenib, regorafenib, and lenvatinib). Results. The expression of ANXA2P2 in HCC tissues was significantly higher than that in adjacent cancerous tissues from TCGA database and validation group. Additionally, patients with high ANXA2P2 expression in HCC tissue had a shorter overall survival, whereas no statistically significant correlation was found between ANXA2P2 expression and disease-free survival (p=0.08) as well as other clinical parameters, such as age, gender, histological grade, T classification, stage, albumin level, alpha-fetoprotein, and vascular invasion (p=0.7323, 0.8807, 0.5762, 0.8515, 0.7113, 0.242, 1.0000, and 0.7685, respectively). Furthermore, in vitro experiments showed that knockdown of ANXA2P2 inhibited migration and invasion of HCC cells but did not have an influence on the HCC cell proliferation when treated with targeted drugs (sorafenib, regorafenib, and lenvatinib). Conclusion. Our study confirmed elevated ANXA2P2 expression levels in HCC tissue compared with adjacent noncancerous tissue and a worse prognosis of patients with high ANXA2P2 levels in the HCC tissue. The newly found properties of promoting migration and invasion of ANXA2P2 in HCC help to explain this phenomenon. ANXA2P2 could be a novel and suitable predicative biomarker for the risk assessment of recurrence or metastasis of HCC patients but may not be effective to predict the efficacy of targeted drugs.

show abstract

“…AnxA2 has been shown to interfere with multiple cellular processes, and particularly in cancer progression. AnxA2 is overexpressed in numerous types of cancer, including colorectal cancer, hepatocellular cancer, esophageal cancer, oral cancer, gastric cancer and pancreatic cancer (39)(40)(41)(42)(43)(44). It is also a serum marker for hepatocellular carcinoma, and has been suggested to have an important role in liver cancer progression.…”

Section: Discussionmentioning

confidence: 99%

“…and cell invasive potential, and interfere with cytoskeleton establishment in tumor cells (40). It has been reported to be a useful biomarker for oral cancer (39). Previous study demonstrated AnxA2 participation in cell proliferation in orbital fat tissue of thyroid orbitopathy patients (45).…”

Section: Downregulation Of Anxa2 In Hepatocellular Carcinoma Cells Hamentioning

confidence: 99%

Downregulation of Calreticulin and Annexin A2 in Cholesteatoma by 2-DE Analysis

Hung

Chien

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Many factors are thought to be associated with the development of cholesteatoma, while the mechanisms of its formation remain unclear. This study aimed to identify the potential mechanisms of the proliferation and growth of cholesteatoma by analysis of the differential expressions of proteins in cholesteatoma and retroauricular skin tissue collected from patients. Methods: Comparative proteomics analyses using two-dimensional gel electrophoresis (2-DE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS), in addition to immunohistochemical analysis, were conducted to identify differentially-expressed proteins in cholesteatoma tissue as compared with retroauricular skin tissue. Western blotting was also employed to verify the expression patterns of the specific proteins identified by 2-DE and to measure the changes in potential modulators related to cholesteatoma proliferation and growth. Results: Calreticulin (CRT) and annexin A2 (AnxA2) were identified as being differentially-expressed in cholesteatoma by 2-DE and LC-MS/MS, the results of which were in agreement with the results of immunohistochemical analysis and western blotting. Downregulation of CRT and AnxA2 were observed in cholesteatoma. Conclusion: Our data suggested that CRT and AnxA2 were associated with cholesteatoma. We speculated that the reduced expression of CRT and the persistent inflammatory response play important roles in the epithelial proliferation of cholesteatoma.

show abstract

Serum Annexin A2 Level Is Associated With Diagnosis and Prognosis in Patients With Oral Squamous Cell Carcinoma

Cited by 13 publications

References 25 publications

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

Clinical significance of Annexin A2 expression in oral squamous cell carcinoma and its influence on cell proliferation, migration and invasion

High Expression of ANXA2 Pseudogene ANXA2P2 Promotes an Aggressive Phenotype in Hepatocellular Carcinoma

Downregulation of Calreticulin and Annexin A2 in Cholesteatoma by 2-DE Analysis

Contact Info

Product

Resources

About